A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents ...

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

An 800% increase in licensing deal values indicates growing confidence in mRNA technology, but some vaccine producers are ...

The FDA approves Pfizer's RSV vaccine, Abrysvo, for adults aged 18-59 years with increased risk of the disease.

However, recent lawsuits filed by GSK against mRNA vaccine producers Pfizer, BioNTech and most recently (15 October) Moderna, have put the licensing of mRNA-based pharmaceuticals in the spotlight.

Recent health news highlights various topics including Abbott's profit rise due to medical device sales, Trump's IVF comments ...

British pharmaceutical company GlaxoSmithKline [USN:L1N3LR0LZ TEXT:“sued Moderna”] in the same Delaware court on Tuesday for allegedly misusing GSK’s LNP technology in its COVID-19 and RSV ...

The vaccine that’s helped protect millions of people worldwide from the COVID-19 virus and its variants would not have been ...

Northwestern University sued vaccine maker Moderna, Inc. on Wednesday, October 16, in the U.S. District Court for the ...

Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle ...